Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks.
Date, time and room information
May 6, 16:30 - 16:45, room Montreal
Category
Clinical stage development company
Speaker information
| Name | Position | Institution |
|---|---|---|
| Berndt Modig | CEO | Pharvaris |
